CAS No. : 1421373-65-0
(Synonyms: AZD-9291 (GMP Like); Mereletinib (GMP Like))
| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15772GL |
| M.Wt: | 499.61 |
| Formula: | C28H33N7O2 |
| Purity: | >98 % |
| Solubility: |
Osimertinib (AZD-9291; Mereletinib) GMP Like is the GMP Like level of Osimertinib (HY-15772). GMP Like small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP Like is an inhibitor that selectively targets EGFRT790M and activated EGFR mutants. Osimertinib GMP Like exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP Like suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP Like modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP Like can be used in research related to radioresistant glioblastoma and non-small cell lung cancer[1][2].
In Vitro:Combination GMP Like with Osimertinib (500-2500 nM; 72 h) and Ganetespib (HY-15205) or Luminespib (HY-10215) enhances the inhibitory effect on cell viability of Osimertinib (HY-15772)-resistant non-small cell lung cancer cell lines PC9-OR2 and PC9-OR4, as well as the parental PC9 and H1975 cell lines[2].
Combination GMP Like with Osimertinib (50 nM; 12 d) and Luminespib significantly reduces the colony-forming ability of PC9, H1975, PC9-OR2 and PC9-OR4 non-small cell lung cancer cell lines[2].
In Vivo:Osimertinib GMP Like (60 μl per 10 g body weight; i.v.; every 48 h) in iRGD-modified liposomal co-delivery with Bortezomib (HY-10227) synergizes with radiotherapy to suppress radioresistant glioblastoma tumor growth and extend median mouse survival to 53.5 days by inhibiting EGFR signaling and DNA repair pathways[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.